Terms: = Germ cell tumor AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
12 results:
1. neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome.
Bogina G; Munari E; Brunelli M; Bortesi L; Marconi M; Sommaggio M; Lunardi G; Gori S; Massocco A; Pegoraro MC; Zamboni G
Histopathology; 2016 Feb; 68(3):422-32. PubMed ID: 26114478
[TBL] [Abstract] [Full Text] [Related]
2. An unexpected role for caspase-2 in neuroblastoma.
Dorstyn L; Puccini J; Nikolic A; Shalini S; Wilson CH; Norris MD; Haber M; Kumar S
Cell Death Dis; 2014 Aug; 5(8):e1383. PubMed ID: 25144718
[TBL] [Abstract] [Full Text] [Related]
3. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract] [Full Text] [Related]
4. Nuclear HER3 is associated with favorable overall survival in uveal melanoma.
Trocmé E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
Int J Cancer; 2012 Mar; 130(5):1120-7. PubMed ID: 21484789
[TBL] [Abstract] [Full Text] [Related]
5. Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.
Boonstra JJ; van Marion R; Tilanus HW; Dinjens WN
J Gastrointest Surg; 2011 Jan; 15(1):48-56. PubMed ID: 20922573
[TBL] [Abstract] [Full Text] [Related]
6. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract] [Full Text] [Related]
7. Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, erbb2, and anti-apoptotic proteins along with histological typing and clinical outcome.
Das P; Puri T; Suri V; Sharma MC; Sharma BS; Sarkar C
Childs Nerv Syst; 2009 Jul; 25(7):825-35. PubMed ID: 19444455
[TBL] [Abstract] [Full Text] [Related]
8. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
[TBL] [Abstract] [Full Text] [Related]
9. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
Haberler C; Slavc I; Czech T; Gelpi E; Heinzl H; Budka H; Urban C; Scarpatetti M; Ebetsberger-Dachs G; Schindler C; Jones N; Klein-Franke A; Maier H; Jauk B; Kiefer A; Hainfellner JA
Eur J Cancer; 2006 Nov; 42(17):2996-3003. PubMed ID: 16996732
[TBL] [Abstract] [Full Text] [Related]
10. clinical relevance of her-2/neu expression in germ-cell testicular tumors.
Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
[TBL] [Abstract] [Full Text] [Related]
11. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
Calabrese C; Frank A; Maclean K; Gilbertson R
J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and her-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
[TBL] [Abstract] [Full Text] [Related]